It is a very good question because the selection of cancer cell line to mimick and predict human responses is still a difficult task.
Herein the abstract of a recent review on this topic:
Despite the millions of dollars spent on target validation and drug optimization in preclinical models, most therapies still fail in phase III clinical trials. Our current model systems, or the way we interpret data from them, clearly do not have sufficient clinical predictive power. Current opinion suggests that this is because the cell lines and xenografts that are commonly used are inadequate models that do not effectively mimic and predict human responses. This has become such a widespread belief that it approaches dogma in the field of drug discovery and
optimization and has spurred a surge in studies devoted to the development of more sophisticated animal models such as orthotopic patient-derived xenografts in an attempt to obtain more accurate estimates of whether particular cancers will respond to given treatments. Here, we explore the evidence that has led to the move away from the use of in vitro cell lines and toward various forms of xenograft models for drug screening and development. We review some of the pros and cons of each model and give an overview of ways in which the use of cell lines could be modified to improve the predictive capacity of this well-defined model. Cancer Res; 74(9); 1–8.
To view the whole review article, please use the following link:
It depends on the cancer cell lines that you are comparing to, for instance if you are using Melanoma your best normal model will be melanocytes or primary epidermal cells. In general you should use normal cells from the same tissue type where the cancer arise.
Most people use HUVEC but that does not necessary be the best model normal cells for your comparison.
I think in your setting the best normal cell line to use is MCF10A it is a breast cell line although it is immortal but it is still attachment dependent for survival and that is a normal feature that cancer cells don't have. HEK293 is derived from embryonic kidney cells and I don't advise.
I agree with the above comments made by Dr. Sirin Adham. You may use PNT2 and MCF10A as normal cell counterparts for LANCaP and MCF7 cancer cell lines.